Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis

Biological therapies have dramatically improved the therapeutic landscape of psoriatic arthritis (PsA); however, 40–50% of patients are primary non-responders with response rates declining significantly with each successive biological therapy. Therefore, there is a pressing need to develop a coheren...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Rahmati, Sara, O’Rielly, Darren D., Li, Quan, Codner, Dianne, Dohey, Amanda, Jenkins, Kari, Jurisica, Igor, Gladman, Dafna D., Chandran, Vinod, Rahman, Proton
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7728744/
https://ncbi.nlm.nih.gov/pubmed/33303908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-78866-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars